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VOYAGER THERAPEUTICS  
- A SPINOUT FROM UMASS  
GENE THERAPY AND RNAI TECHNOLOGIES  
 
Guangping Gao, PhD 
CCTS Mini Symposium  
May 20, 2016 
 
GENE THERAPY STRATEGIES: AN OVERVIEW 
DISCLOSURE 
1. G. Gao is a cofounder of Voyager Therapeutics, a 
biopharmaceutical company and holds equity in the 
company.   
 
2. G. Gao is an inventor on patents with potential 
royalties licensed to Voyager and other 
biopharmaceutical companies.  
GENE THERAPY STRATEGIES: AN OVERVIEW 
Cost: $3 Billions 
G
T 
GT drug development: 
- starts with a specific therapeutic agent 
- skips the drug discovery phase 
Cost: $ 0.6 Billion 
DRUG DEVELOPMENT  
- CONVENTIONAL VERSUS GENE TX  
First human 
gene therapy for 
ADA Via retrovirus  
(Sept 14,1990) 
First lentivirus  
against HIV 
(2003) 
Clinical trial for X-linked ALD (2014) 
CAR-T-cell therapy (2011) 
Jesse Gelsinger  
(Sept 17,1999) 
First adenovirus for cystic fibrosis (1993) 
First AAV for CFTR(November 1995) 
Discovery of AAV8 (2002) 
Glybera approved by EMA (2012) 
AAV8 to treat hemophilia B (2011) 
AAV2 gene transfer to treat LCA (2008) Gao G entered  
The field (1994) 
PROGRESS IN GENE THERAPY 
- DRIVEN BY VECTOR PLATFORM DEVELOPMENT 
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 More Gene Tx companies founded and went public 
 More and more investment $ into Gene Tx 
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COMMERCIALIZATION OF GENE THERAPY  
- RAPID TRANSFORMATION IN THE PAST FEW YEARS 
 AAV companies go to IPO fast r & faster  
 More than 200 gene therapy companies globally 
WHY UMMS? 
- A WORLD LEADER IN RNAI, DEGENERATIVE NEUROLOGICAL  
DISEASE RESEARCH & AAV GENE THERAPY 
• Our faculty have made key advances 
– World leading scientists in RNAi research (Mello, Ambros, & Zamore) 
– World leading physician scientists in neurodegenerative disorders  
 Brown for Amyotrophic Lateral Sclerosis  
Aronin for Huntington Disease 
– World leading rAAV gene therapy scientists  
 First to discover novel primate AAVs for efficient and stable gene transfer (Gao, 2002) 
 First to use AAV gene therapy in patients with 4 INDs (Flotte 1995) 
• Horae Gene Therapy Center 
– A >12,000 Ft2 state-of-art research facility on the 6th floor of  Albert Sherman Building 
– Research home for 15 faculty and affiliated faculty members, > 60 trainees and staff    
IMPORTANT MILESTONES IN  
FOUNDING & GROWING OF VOYAGER   
| | | | | | 
2009 2012 2013 2014 2015 2016 
Voyager  
IPO  
$225 M cash 
Initially approached 
by  3rd Rock Venture 
Re- engagement  by 
3rd Rock Venture 
Continued discussions 
w/t 3RV on “AAVian” 
Voyager signed license agreement  with 
UMMS for RNAi and rAAV 
technology platforms 
$45 M series A funding by 3RV & 
formally launching of Voyager   
$845 M committed  by Sanofi/Genzyme for strategic 
collaboration w/t Voyager in CNS gene therapy   
Voyager secured $60 M series B 
funding from  “Crossover” investors 
Company Founders 
10 © Voyager Therapeutics 
 
Voyager was founded by world leaders in the fields of AAV gene 
therapy, expressed RNA interference and neuroscience. 
 
Krystof Bankiewicz, M.D., Ph.D. 
Kinetics Foundation Chair in Translational Research and Professor in Residence of 
Neurological Surgery and Neurology, University of California at San Francisco 
 
Guangping Gao, Ph.D. 
Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & 
Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular 
Genetics and Microbiology, UMMS 
 
Mark Kay, M.D., Ph.D. 
Dennis Farrey Family Professor, Head, Division of Human Gene Therapy, Departments of 
Pediatrics and Genetics, Stanford University School of Medicine 
 
Phillip Zamore, Ph.D. 
Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical 
Sciences, Professor of Biochemistry and Molecular Pharmacology, and Co-Director of the 
RNA Therapeutics Institute, University of Massachusetts Medical School (UMMS) 
Company Highlights 
11 © Voyager Therapeutics 
Robust product engine to engineer, optimize, manufacture and 
deliver AAV gene therapies 
Pipeline of five programs for severe CNS diseases 
Lead program, VY-AADC01, for advanced Parkinson’s disease with 
human POC expected in H2:2016 
Strategic collaboration with Genzyme — gene therapy “know-how” 
Strong financial position with ~$225 million of cash following IPO in 
November 2015, no debt 
Management team and scientific founders that have pioneered 
significant advances in AAV gene therapy and neuroscience, and have 
extensive CNS drug development expertise (Steve Paul, MD, CEO)  
Treating Severe CNS Diseases with AAV Gene Therapy 
• Significant unmet medical need 
• Genetically-validated targets 
• Targeted delivery to regions of the 
brain & broader delivery to the spinal 
cord is achievable  
• Durable transgene expression as CNS 
cells are terminally differentiated 
• Immune-privileged site 
Why CNS? 
• Ability to target a variety of tissue & cell 
types within the CNS 
• >1,300 patients (200 in CNS) treated, 
no AAV-related SAEs to date 
• AAV does not readily integrate into the 
target cell genome, reducing potential 
for oncogenesis 
• Ability to manufacture at commercial 
quality and scale 
Why AAV? 
12 © Voyager Therapeutics 
Product Engine Driving Pipeline of AAV Gene Therapies 
13 © Voyager Therapeutics 
Product Engine Pipeline of 5 Programs 
VY-AADC01 
Advanced 
Parkinson’s  
Disease 
VY-SOD101 Monogenic Form of ALS 
VY-FXN01 Friedreich’s Ataxia 
VY-HTT01 Huntington’s Disease 
VY-SMN101 
Spinal 
Muscular 
Atrophy 
U.S. Ex-U.S.  
(option to worldwide) 
(option to  
co-U.S.) 
Genzyme 
(option) 
Genzyme 
Genzyme 
(option) 
Genzyme 
(option) 
Genzyme 
Phase 1 Preclinical Commercial Rights Program 
Process R&D & 
Manufacturing 
Vector  
Engineering  
& Optimization 
Dosing &  
Delivery 
Techniques 
® 
® 
® 
® 
• Process R&D center at 
Voyager’s headquarters 
• Research grade 
baculovirus / Sf9 
production system 
• Up to 250L bioreactor 
capacity  
• Proprietary reagents for 
new capsids and 
constructs 
• Collaboration with 
MassBiologics 
• cGMP baculovirus / Sf9 
production system 
• Up to 1,000L bioreactor 
capacity  
• Voyager retains IP and 
key process know-how 
Commercial Scale AAV Manufacturing Capabilities 
• Collaboration with 
UMass Medical School 
• Research grade 
baculovirus / Sf9 
production system 
• Up to 500L bioreactor 
capacity 
Process R&D 
Large Scale Research 
Capacity 
Commercial Scale 
cGMP Capacity 
14 © Voyager Therapeutics 
Robust Strategic Collaboration with UMMS 
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• Pilot grant program 
focused on understanding 
& optimizing AAV vectors 
for therapeutic use  
• Licenses and sponsored 
research focused on 
novel AAV technology 
• Opportunities for UMMS 
participation in Voyager 
clinical trials 
• Postdoctoral training 
program 
• Sponsorship of annual 
lecture series on AAV-
mediated gene therapy 
• Opportunities for Voyager 
to support graduate 
fellowships in the area of 
central nervous system 
AAV gene therapy 
• AAV vector supply from 
the UMMS Gene Therapy 
Vector Core to support 
Voyager research 
projects 
• Partnership with 
MassBiologics to  
advance AAV process 
development & GMP 
production for Voyager 
product programs 
Research 
Collaboration 
Production & 
Manufacturing 
Educational  
Support 
Voyager and UMMS collaborate under a broad strategic partnership to advance 
AAV gene therapy research, manufacturing and education 
